Eli Lilly (LLY) has agreed to acquire biotechnology company Orna Therapeutics for up to $2.4B in cash, inclusive of an upfront payment and subsequent payments upon achievement of certain clinical ...
Eli Lilly is acquiring in vivo cell therapy-focused biotech, Orna Therapeutics, in an immunology deal worth up to $2.4bn. Through the agreement, Lilly will gain access to Orna’s new class of circular ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results